TANDEM MOBI SYSTEMThe world’s
smallest, durable AID system ¹

* CGM sold separately.

† With optimized correction factor based on “rule of less than 1600”.

‡ Our mobile apps require a compatible smartphone model and operating system (sold separately). Only available to pump users who reside in the U.S.

§ Do not wear or place your pump more than 12 inches (30.5 cm) above your infusion site. Doing so may result in over delivery of insulin.

^ Tandem Mobi adhesive sleeve sold separately.

** Tested at 8 feet for 2 hours (IP28 rating).

†† Precaution: Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. To use Share/Follow the smartphone must be within 10 meters of the Dexcom G7. Always pair the Dexcom G7 sensor with your Tandem system before pairing with the Dexcom G7 app and Apple Watch. The Tandem system communicates directly with the Dexcom G7 sensor to get CGM readings, and does not communicate with the Dexcom G7 app or Apple Watch. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.

‡‡ Future updates for all or some Tandem products may not be developed and may not be offered everywhere and would be subject to applicable regulatory approvals. Software updates are only available to customers who are in warranty at the time they update their pump. Additional training may be required to access certain software updates. Charges may apply. Tandem may discontinue select software and features over time at its discretion.

References

Note: Studies were conducted using a t:slim X2 insulin pump with Control-IQ technology and a Dexcom G6 sensor.

1. As of June, 2025. Data on file, Tandem Diabetes Care.

2. Messer LH, Breton M. Diabetes Technol Ther. 2023;25(12):877-882.

Important Safety Information

RX ONLY.

Indications for Use

Tandem Mobi system: The Tandem Mobi insulin pump with interoperable technology (the pump) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The Pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in persons 2 years of age and greater.

t:slim X2 insulin pump: The t:slim X2 insulin pump with interoperable technology (the pump) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in persons 2 years of age and greater.

Control-IQ+ technology: Control-IQ+ technology is intended for use with compatible integrated continuous glucose monitors (iCGM, sold separately) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ+ technology is intended for the management of type 1 diabetes mellitus in persons 2 years of age and greater and of type 2 diabetes mellitus in persons 18 years of age and greater.

Warning: Control-IQ+ technology should not be used in anyone under the age of 2 years old with type 1 diabetes or under the age of 18 years old with type 2 diabetes. It should also not be used in patients who require less than a total daily insulin dose of 5 units of insulin per day or who weigh less than 20 pounds (9 kilograms), as those are the required minimum values needed for Control-IQ+ to operate safely.

Users of the pump and Control-IQ+ must: use the insulin pump, iCGM, and all other system components in accordance with their respective instructions for use. Failure to follow these instructions for use could result in an over delivery or under delivery of insulin.  This can cause hypoglycemia (low BG) or hyperglycemia (high BG) events. Visit tandemdiabetes.com/safetyinfo for additional important safety information.

These infusion sets are indicated for the subcutaneous infusion of insulin administered by Tandem insulin pumps for the treatment of diabetes. These infusion sets are indicated for single use. For contraindications, warnings, precautions, and other important information, please refer to the instructions for use accompanying the infusion sets.